Proteomic Identification of Putative Biomarkers of Radiotherapy Resistance: A Possible Role for the 26S Proteasome?

Abstract

These findings suggest that the 26S proteasome may provide a general predictive biomarker for radiotherapy outcome.

Breast cancer subtypes: response to radiotherapy and potential radiosensitisation

“…However, the question remains as to whether these breast cancer subtypes may be used to predict response to RT or whether specific subtypes may benefit from radiosensitising agents to enhance the efficacy of this treatment. Data from our in vitro studies have shown that breast cancer cell lines representing the different subtypes exhibit differential inherent sensitivities to ionising radiation [28], which suggests that this may certainly be feasible. A clear advantage of being able to exploit these markers for selecting patients for RT is that their expression is already routinely analysed within the clinic for diagnostic and prognostic purposes and also for selecting patients for other breast cancer therapies.…”

Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling

“…It was recently estimated that one-half to two-thirds of cancer patients receive radiation therapy in curative or palliative settings during their disease [1,2]. Radiotherapy is a therapeutic approach with a very high potential for local control: ionizing radiation is equally as effective as surgery in curing prostate [3,4], laryngeal [5], cervical [6], and anal cancers [7].…”

PSMA7 Directly Interacts with NOD1 and Regulates its Function

“…Recent findings indicated the relationship between PSMA7 expression and the clinicopathological features of colorectal cancer and suggested that PSMA7 may be molecular targets for colorectal cancer therapy [5,6,16]. However, it is unknown how PSMA7 critically regulates the tumorigensis of colorectal cancer cells.…”